Back to all news
OpenEvidence Hits $12B Valuation as Clinical AI Adoption Surges, AI Chatbots Named Top 2026 Healthcare Hazard
OpenEvidence becomes the leading AI platform among U.S. physicians, securing a $12B valuation amid rising concerns about AI chatbot misuse in healthcare.
Key Details
- 1OpenEvidence raises $250M, now valued at $12B, doubling its valuation since October; exceeds $100M annual revenue.
- 2The platform's flagship product supported 18M U.S. physician consultations in December, up from 3M/month a year prior.
- 3Over 40% of U.S. doctors now use OpenEvidence, with 100M+ patients treated via its tools in 2025.
- 4Amazon launches an AI health assistant within its One Medical app, continuing Big Tech's push into clinical AI ecosystems.
- 5ECRI cites 'misuse of AI chatbots' as the #1 health tech hazard for 2026, highlighting serious risks in clinical settings.
Why It Matters
These developments exemplify both the rapid integration and scaling of clinical AI platforms and the urgent need for oversight to mitigate risks—especially as AI becomes more deeply embedded in healthcare. For radiology and imaging AI, these trends spotlight key adoption metrics, the growing ecosystem, and the importance of responsible deployment.
Source
HealthExec
Related News
•Radiology Business
Lucida Medical Raises $11M for AI-Based Prostate MRI Diagnosis Expansion
Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.
•Radiology Business
Radiologists Push Back Against AI CEO's Claims of Specialty Replacement
Radiologists challenge Anthropic CEO Dario Amodei's assertion that AI has already replaced their core tasks.
•Radiology Business
Harrison.ai Petitions FDA for CAD Device Premarket Review Exemption
Harrison.ai has petitioned the FDA to exempt some radiology AI devices from premarket review, prompting mixed feedback from industry stakeholders.